According to Synspira Therapeutics, the company’s SNSP113 inhaled glycopolymer for the treatment of cystic fibrosis has received orphan drug desination from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP). The FDA granted orphan drug designation to SNSP113 in October 2018.
The company said that it has received funding from Cystic Fibrosis Foundation Therapeutics that will support a clinical study planned for later this year.
Synspira President and CEO Robert Gallotto commented, “With orphan designation in both the US and EU, we have achieved an important milestone in our global regulatory strategy and are committed to advancing SNSP113 as a novel approach to treating this debilitating disease. We believe that SNSP113 has the potential to be the first broad spectrum therapy to improve pulmonary function in patients with CF and look forward to working with the EMA as we progress the program.”
Read the Synspira Therapeutics press release.
